MDT-AP-2085
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 7
- sex
- F
- new_clusters
- C2
- umap1_2d
- 3.10393566
- umap2_2d
- 1.061122097
- umap1_3d
- -0.001620698
- umap2_3d
- -2.660946298
- umap3_3d
- -1.525677852
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.520
- G2M_CHECKPOINT+0.510
- E2F_TARGETS+0.490
- MYC_TARGETS_V2+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.380
- PROTEIN_SECRETION+0.370
- MTORC1_SIGNALING+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- DNA_REPAIR+0.270
- MITOTIC_SPINDLE+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- APICAL_SURFACE-0.460
- ANGIOGENESIS-0.450
- INTERFERON_GAMMA_RESPONSE-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INFLAMMATORY_RESPONSE-0.350
- MYOGENESIS-0.320
- ALLOGRAFT_REJECTION-0.310
- APICAL_JUNCTION-0.310
- ESTROGEN_RESPONSE_EARLY-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.915 |
| 2 | MDT-AP-0714 | Med | Medulloblastoma | 0.903 |
| 3 | 004064de-0e10-491d-b3d8-bc628a8f70a8 | — | — | 0.901 |
| 4 | TCGA-C8-A1HN-01A-11R-A137-07 | — | B | 0.900 |
| 5 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.897 |
| 6 | TCGA-51-4080-01A-01R-1100-07 | — | cohortSQ2 | 0.888 |
| 7 | BS_TV5B86ZD | Embryonal tumors | — | 0.886 |
| 8 | MDT-AP-3088 | Med | Medulloblastoma | 0.886 |
| 9 | BS_052PZFMK | high-grade glioma | — | 0.884 |
| 10 | SRR12202462 | — | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |